 |



FACES
Blending the clinical
and the statistical
From sleepless nights and a study of narcolepsy to
chairing a leading program

A rebel with “medicine in his veins” becomes
a scientific researcher in India


ALUMNI

2006-2007 Association of Yale Alumni in
Medicine 
NOTES

Alumni notes

Lee Goldman, executive vice president for health and biomedical sciences
at Columbia University’s College of Physicians and Surgeons,
is known for his work in combining epidemiology with clinical care
in cardiology.

|
|
Blending
the clinical and the statistical
Early in his career, Lee Goldman saw the value of applying
epidemiology to clinical practice.
For more than two decades physicians have carried in their pocket copies
of the Goldman Index, a list of factors to determine whether a patient
undergoing surgery for noncardiac reasons is at risk of a heart attack
or another major cardiac complication. The index is named for Lee
Goldman, M.D. ’73, M.P.H. ’73, FW ’78, who
developed it during his medical residency and published it during his
cardiology fellowship at Yale by applying techniques derived from epidemiology
and clinical practice.

In recent years Goldman has also achieved renown for his leadership of
the department of medicine at the University of California, San Francisco
(UCSF), which he joined in 1995. In July 2006 Goldman moved to Columbia
University’s College of Physicians and Surgeons as executive vice
president for health and biomedical sciences and dean of the faculties
of health sciences and medicine.

Goldman traces his interest in statistics to a class he took during his
first semester at the School of Medicine with John D. Thompson, R.N.,
M.S., the legendary director of the program in hospital administration
at the Department of Epidemiology and Public Health. That course convinced
Goldman to enroll in Yale’s master of public health program, and
a study he undertook there cemented his love of numbers and other data.
In 1971, President Richard Nixon was pushing a plan for national health
insurance. Goldman surveyed Yale medical students and faculty, deconstructing
this bill and competing pieces of legislation to determine how his colleagues
should perceive each proposal. Goldman then took his programming textbook
to the beach over Labor Day weekend and came back ready to crunch numbers
in the giant computers of the day. As the analysis came together, he
was hooked. “I ended up publishing five papers out of my thesis,”
he said, “and kind of got the bug.”

He soon began to apply his new-found statistical and programming savvy
to studies of cardiac risk. After an internship and residency at UCSF
and a second residency at Massachusetts General Hospital, Goldman became
a cardiology fellow at Yale. As his fellowship ended, Goldman said, his
interest in epidemiology propelled him toward nontraditional applications
of cardiology. “Cardiology divisions weren’t really interested
in me, and I didn’t really want to run an echo [cardiogram] lab,”
he said.

In the division of general internal medicine at Harvard’s Peter
Bent Brigham (now Brigham and Women’s) Hospital, where he stayed
for almost two decades, Goldman continued to focus on combining epidemiology
with clinical care in cardiology. “Most of my work used the same
kinds of methods an epidemiologist used, but applied it to patients we
actually touched,” he said, describing his efforts to determine
risk factors for heart attacks after surgery and among patients who came
to emergency rooms with chest pain. “There were so many factors
to consider that clinicians did not have a way of determining which ones
were the best predictors of a patient’s risk,” he said. “The
concept was always to gather comprehensive data and to whittle it down
to what might be important.”

One of Goldman’s most enduring contributions was the Goldman Index.
“It was the first systematic approach to that question,” said
Lawrence S. Cohen, M.D., HS ’65, special advisor to the dean. “It
has remained a benchmark for the care of patients that are undergoing
noncardiac surgery, and it has stood the test of time over three decades.”

Goldman and his colleagues also started one of the first chest pain evaluation
units at Harvard. Today, these are common at many hospitals nationwide.
And Goldman developed the Coronary Heart Disease Policy Model, which
sets priorities for preventing and treating heart disease. At Harvard,
he also codeveloped the Program in Clinical Effectiveness, which has
trained over 1,000 young physicians in the basics of clinical research.

“He really has been a pioneer,” said Harlan M. Krumholz,
M.D., M.Sc., the Harold J. Hines Jr. Professor of Medicine and professor
of epidemiology and public health, and of investigative medicine, one
of Goldman’s advisees at Yale. “He was one of the first people
to develop large observational studies that drew knowledge from the real
world and could be fed back into practice.”

After becoming the chair of medicine at UCSF, Goldman and his colleague
Robert M. Wachter, M.D., in 1996 coined the term hospitalist for
inpatient physicians, a concept that quickly produced a major movement
in medicine. (Goldman and Wachter started the first hospitalist program
in the country at UCSF.) With inpatient care changing rapidly, they argued,
office-based doctors simply do not have time to monitor their hospital
patients the necessary three or four times a day. Establishing a separate
specialty of hospital medicine, they argued, would increase hospital
efficiency and benefit patients. “The board is about to recognize
it as a distinct discipline,” he said, referring to the American
Board of Internal Medicine, which certifies subspecialties in internal
medicine.

“Columbia is fortunate,” said his former advisee Krumholz,
recalling his mentor’s seemingly limitless capacity to inspire
students and colleagues. “When he walked into a room, the energy
would just increase, the quality of conversation would go up. I think
a whole generation of people was drawn to research because of their association
with him.”

—Alla Katsnelson


 |
|



|
|
 |
David Kupfer’s meeting with a mentor in his second year of medical
school set him on a path toward his career in psychiatry.
|
|

When most lights in the dormitory went out, David Kupfer’s
stayed on. A history and economics major at Yale College, Kupfer, M.D.
’65, couldn’t understand why his peers needed so much sleep.
At the time, he didn’t realize sleep would influence his career—that
he would become a leader in sleep, depression and bipolar disorder research—and
that observing two cases of narcolepsy would set him on this path.

While in medical school and still undecided about a specialty, Kupfer
saw two patients at Yale-New Haven Hospital (YNHH) who suffered from
an extreme exhaustion called cataplexy that results in a complete loss
of muscle control. Both were also diagnosed with narcolepsy.

Seeing these two patients solidified Kupfer’s decision to study
sleep, but two encounters with a Yale professor molded his career. As
a second-year student he met Thomas Detre, M.D., then chief of psychiatry
at YNHH, whose interests included recurrent depression, violence and
aggression in children, biologic aspects of mental disorders and the
budding fields of psychobiology and psychopharmacology. At a time when
there was little understanding of mental diseases, Detre felt that understanding
the body could lead to better treatment of mental illness.

During Kupfer’s third year, a last-minute trade with a classmate
led to a chance reunion with Detre and solidified Kupfer’s decision
to pursue psychiatry. The night before beginning his psychiatry rotation
at the VA hospital in West Haven, Kupfer agreed to switch rotations with
a classmate who wanted to work at the VA. Kupfer was back at YNHH with
Detre. They soon realized they had a lot in common—both were high-energy
and stayed up late. Detre expected diligence and Kupfer delivered.

“Some people have considered [Detre] a tough taskmaster because
he was so persistent. I found him loyal and supportive and clever. He
gave me freedom,” Kupfer said.

After medical school, Kupfer trained at the National Institute of Mental
Health (NIMH), then returned to Yale in 1969 as an NIMH investigator
and assistant professor of psychiatry. Kupfer’s career was blossoming
at Yale, but Detre asked him to join him at the University of Pittsburgh
and its Western Psychiatric Institute and Clinic (WPIC), which Detre
felt he could transform to better treat patients with mental illness.
In 1973, Kupfer went to Pitt as an associate professor of psychiatry
and director of research. In 1983, he became director of the WPIC and
chair of the Department of Psychiatry when Detre became senior vice chancellor
for health sciences. In 1994, further cementing the connection between
these remarkable colleagues, Kupfer was named the first Thomas Detre
Professor of Psychiatry.

Finally retired from his 23-year career as vice chancellor, Detre now
serves as a professor emeritus of psychiatry and is teaching a course
to residents on psychiatric diagnosis. He sits on the boards of two software
companies in Pittsburgh and is also on the scientific advisory board
of PsychoGenics, a New York-based company that tests neurological drugs.

At Pitt, Kupfer stressed the importance of determining the biological
underpinnings of psychiatric disease and led a research revolution by
earning a number of NIMH grants for research on sleep disturbances, depression
and bipolar disorder. The number of faculty and beds increased, along
with the reputation of Pitt’s psychiatry program. “From 1983
to 1993 the department went from Number 4 to Number 1 in federal research
funding,” Detre explained.

With his wife, Ellen Frank, Ph.D., Kupfer co-directs the Bipolar Disorder
Center for Pennsylvanians, created with a $5 million grant from the commonwealth.
He is principal investigator of several studies, including one on the
pharmacogenetics of bipolar disease.

“You’re going to laugh when I say this—writing is very
difficult for me,” he said. He has written 800 articles, books
and book chapters. His latest book, written for a general audience with
Helena Chmura Kraemer, Ph.D., and Karen Kraemer Lowe, M.S., is titled To
Your Health: How to Understand What Research Tells Us About Risk,
and stresses the importance, throughout medicine, of designing more rigorous
clinical trials and clearly defining the results. As a case in point
Kupfer cites media reports of studies that appeared to show a high risk
of suicide among young children on antidepressants. According to Kupfer,
many of the studies poorly defined the risk.

Kupfer hopes that someday more physicians will value the relationship
between mental and physical illnesses. Research has shown that depression,
for example, makes people more susceptible to other illnesses, like diabetes.
Kupfer feels that many doctors treat the diabetes rather than exploring
the link between the depression and diabetes. He hopes this paradigm
changes soon—patients who receive poor mental health treatment
face serious health risks, just like patients who receive the wrong medical
care.

It might keep Kupfer up at night, but that’s when he does his best
work.

—Meghan Holohan


 |
 |
 |
Manohar Shirodkar has spent his career, in India and the United States,
studying oncogenic viruses.
|
|
A rebel with “medicine
in his veins” becomes a scientific researcher in India
When Manohar V.N. Shirodkar, Med ’54, M.D.,
initially rebelled against a family tradition and rejected medical practice,
his father, a famed gynecologist in Mumbai, India, despaired. The young
Shirodkar knew he had “medicine in his veins”—his father
had developed the Shirodkar stitch, which is still used to treat cervical
incompetence. But Shirodkar wasn’t interested in being a clinician.

Shirodkar, however, found something more exciting—the viral causes
of illness. When he learned that his grandmother had died of cervical
cancer, Shirodkar was hooked. How did she get sick? Why would she have
cancer when others do not? Today, the medical community knows that some
types of the human papilloma virus can cause cervical cancer, but at
that time the young man simply knew that one way to understand illness
was to study oncogenic viruses.

To his father’s delight, Shirodkar begged to study medicine in
the United States. After he completed his undergraduate work at Johns
Hopkins University, he headed to the Yale School of Medicine in 1950.
His clinical studies were interrupted when Shirodkar learned his wife
was pregnant. The couple returned to Mumbai, where their daughters, Renée
and Diane, were born. With a growing family, Shirodkar didn’t have
the funds to complete medical school. He accepted a position at Johns
Hopkins’
school of public health, which gave him a stipend to pursue an Sc.D.

His detour from a traditional medical education gave Shirodkar the opportunity
he wanted. (He finished his M.B.B.S. in 1970 at the Seth G.S. Medical
College in Mumbai.) And throughout a career filled with many twists and
turns, his drive to understand viruses remains constant.

As a graduate student at Hopkins in 1958, Shirodkar began investigating
the Rous sarcoma virus in chickens, the first virus discovered to cause
a solid cancer. His research took him from Hopkins to the Virus Research
Center of the Rockefeller Foundation in Pune, India, where he completed
his doctoral thesis. In 1978 he found that West Nile virus, and later,
rabies, blocked the Rous-produced sarcoma, and that the underlying mediator
was not interferon, but his newly discovered anti-sarcoma, antiviral
protein, called plasma factor. His research findings appeared in The
Journal of Immunology in December 1965, the Journal of General
Virology in 1973, The Indian Journal of Medical Research in
1978 and the Indian Journal of Experimental Biology in October
2006.

“The most gratifying aspect of my career,” Shirodkar said,
“is the fact that I have been a perpetual student—quite literally—and
have been able to pursue, with some success, ... the search for scientific
truth.”

As a young man, Shirodkar turned away from a career as a clinician, yet
he always admired his father. In 1976, Shirodkar and his wife, Sudha,
founded the Dr. V.N. Shirodkar Memorial Research Foundation, an organization
that embodies the dreams of both Shirodkar and his father. The organization
screens underprivileged women for cervical cancer and investigates novel
antiviral biological agents to treat virus diseases.

—M.H.


 |
 |